ALS Digital Twin Generator (DTG)
Disease-specific digital twin model for ALS clinical trials
Model · Cloud SaaSCompany source
Company profile
About Unlearn.AI
Unlearn.AI uses AI to create digital twins of clinical trial participants, streamlining clinical development and enabling confident decision-making.
Company description Unlearn.AI official website
Primary marketClinical Trials & Research
Commercial modelCommercial information available on request
Work at Unlearn.AI?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Alzheimer's disease
- Amyotrophic Lateral Sclerosis (ALS)
- Asthma
- Atopic Dermatitis
- COPD
- Coronary Artery Disease
- Crohn's disease
- Dyslipidemia
- Frontotemporal dementia
- Huntington's disease
- Hypertension
- Migraine
- Obesity
- Osteoarthritis
- Osteoporosis
- Parkinson's disease
- Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- SCI
- Stroke
- Type 2 Diabetes
- Ulcerative Colitis
Who it serves
- Biotechnology companies
- Clinical research organizations
- Pharmaceutical companies
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsEurope · United States
Company sourceOfficial website
Company milestones
Platform expansion
January 2026: Introduced TrialPioneer AI-powered workspace for upstream trial planning. February 2026: Partnership with VectorY Therapeutics for PIONEER-ALS Study. April 2025: Partnership with remynd for Alzheimer's study. April 2025: Partnership with Trace Neuroscience for ALS trial optimization. September 2024: ProJenX partnership for ALS trial.
Partnerships
Recorded partners
- AbbVie
- Johnson & Johnson
- ProJenX
- QurAlis
- remynd
- Roche
- Trace Neuroscience
- VectorY Therapeutics
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Anomaly Detection & Clinical Data Surveillance
Continuous patient and site-level monitoring of clinical data
Software · Cloud SaaSCompany source
Digital Twins
AI-generated forecasts of patient control outcomes for clinical trials
Model · Cloud SaaSCompany source
Hindsight
Explore harmonized clinical trial and real-world datasets
Platform · Cloud SaaSCompany source
Scout
Continuously search and summarize clinical literature and regulatory precedent
Software · Cloud SaaSCompany source
SimLab
Build and compare trial-design scenarios with reproducible evidence
Software · Cloud SaaSCompany source
TrialPioneer
AI-powered workspace for upstream trial planning and design decisions
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Synthetic Data in Healthcare and Drug Development: Definitions, Regulatory Frameworks, Issues.CPT: pharmacometrics & systems pharmacology · May 1, 2025
Using AI-generated digital twins to boost clinical trial efficiency in Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.) · Jan 1, 2025
Patellar tendon biomechanical and morphologic properties and their relationship to serum clinical variables in persons with prediabetes and type 2 diabetes.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · Aug 1, 2024
Increasing acceptance of AI-generated digital twins through clinical trial applications.Clinical and translational science · Jul 1, 2024
The cortisol awakening response in a 3 month clinical trial of service dogs for veterans with posttraumatic stress disorder.Scientific reports · Jan 18, 2024
Looking ahead in early-phase trial design to improve the drug development process: examples in oncology.BMC medical research methodology · Jun 29, 2023
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Control arm size reduction
33% reduction in control arm size
Enrollment time saved
4+ months saved in enrollment time
Statistical power
Maintain statistical power with fewer participants or boost power without adding participants
Trial efficiency
Earlier go/no-go decisions with clearer signals at every interim timepoint
VectorY Therapeutics
Applying AI-generated digital twins to the PIONEER-ALS study
Enhanced trial design and analysis for ALS clinical development
remynd
Using digital twins in Phase 2a Alzheimer's trial to predict disease progression and support early signals of efficacy
Increased confidence in pioneering approach towards symptomatic relief and disease modification in Alzheimer's
Trace Neuroscience
Optimizing ALS Phase 1/2 trial design using the ALS Digital Twin Generator to explore smarter designs and make confident decisions
Enabled faster decision-making for people living with ALS waiting for new treatment options
ProJenX
Augmenting ALS clinical trial PRO-101 with digital twin model to provide built-in placebo controls for each participant in open-label study
Improved confidence in early-stage clinical trial data with person-intraperson comparison advantages over propensity score matching
Johnson & Johnson
Accelerating randomized clinical trials in Alzheimer's disease using generative machine learning model forecasts of disease progression
Faster trial timelines through AI-powered disease progression forecasting
Roche
Evaluating digital twins for Alzheimer's disease using data from a completed Phase 2 clinical trial
Validated digital twin methodology in Alzheimer's disease trials
AbbVie
Accelerating clinical trials in Alzheimer's disease using digital twins to reduce control arm size and enrollment time
33% control arm size reduction and 4+ months enrollment time saved
QurAlis
Streamlining efficiency of QRL-201 randomized control trial and increasing confidence of results with generative AI technology
Improved trial efficiency and result confidence in ALS clinical trial
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Unlearn.AI
Recent articles published on Unlearn.AI's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Clinical Trials & Research
Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.